ClinicalTrials.gg
Active, not recruitingNCT05859620ImplementPMIUpdated May 5, 2026

Implementation of a Clinical Screening and Response System for Cardiac Complications After Noncardiac Surgery

An observational study in Myocardial Injury, Myocardial Infarction and Perioperative Complication, sponsored by University Hospital, Basel, Switzerland. Active, not recruiting at 5 sites in 2 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by University Hospital, Basel, Switzerland · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
900
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Myocardial Infarction with a site in Switzerland — 14 open to participants now, 20 under way, 5 of them phase 3. Myocardial Infarction · Switzerland.

Planned enrollment
11th of 18
900 · median 1,526
Started
2021
with 9 others
Observational
18 of 69
5 open now
Primary completion
2026-12
later than 4 of 19 live
Registered
58th of 69
by date
Lead sponsor
7 of 69
University Hospital, Basel, Switzerland

Among the 69 studies in Myocardial Infarction with a site in Switzerland, this one is the 11th largest by planned enrollment of the 18 observational ones that give a count, is one of 10 that started in 2021, is one of 18 observational ones, reaches primary completion later than 4 of the 19 other live ones, and was the 58th registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

14 of the 69 studies in Myocardial Infarction with a site in Switzerland are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Myocardial Infarction with a site in Switzerland, or all of them as a file.
02

Study summary

The investigators aim to show the feasibility and medicoeconomic impact of implementing a clinical screening and response system for the early detection of perioperative cardiac complications in high-risk patients.

Specifically, the investigators aim to: 1) evaluate the feasibility of implementation of a PMI-screening; 2) evaluate the medicoeconomic impact of implementing a PMI-screening; 3) identify barriers to implementation; 4) generate data for a future randomized controlled trial on outcomes by exploring opportunities to improve care following PMI, the occurrence and timing of major adverse cardiac events (MACE), and the treatment effect associated with PMI-screening.

Read the detailed description

Background: Perioperative myocardial infarction/injury (PMI) is increasingly recognised as frequent, but often undiagnosed and untreated contributor to mortality following noncardiac surgery. Due to differences in pathophysiology and perioperative anaesthesia and analgesia, most PMI do not cause typical ischemic symptoms and are therefore missed in routine clinical practice. Active surveillance using cardiac troponin (cTn) is now guideline-recommended for the early detection of PMI to possibly improve outcome1. Given substantial concerns regarding the feasibility and health economic impact of implementing such a strategy, it is not yet widely applied.

Aim: to show feasibility of implementation as well as health economic impact of an active surveillance for the early detection of PMI in high-risk patients.

Methodology: in this observational before-after study the investigators will enrol patients at high cardiovascular risk undergoing noncardiac surgery before and after implementation of a PMI screening. Patients in the pre-implementation phase will receive standard of care, while in the post-implementation phase patients receive a PMI-screening, consisting of a preoperative and two postoperative measurements of high-sensitivity cTn (hs-cTn) and a cardiology consultation will be done in case of detection of a PMI. Patient data, resource utilisation, and PMI-aetiology will be collected. Interviews with key stakeholders will identify barriers to implementation. One-year follow-up will be conducted to evaluate occurrence of death, MACE, and safety endpoints.

Potential significance: This study will generate important insights regarding the feasibility, safety and the health economic impact of implementing an active surveillance for the early detection of PMI.

03

Conditions studied

  • Myocardial Injury
  • Myocardial Infarction
  • Perioperative Complication

Keywords

  • Myocardial injury
  • Myocardial infarction
  • Perioperative care
  • Noncardiac surgery
  • Screening
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients aged 40-85 years at increased cardiovascular risk undergoing inpatient, noncardiac, elective or emergent surgery with a planned postoperative stay of ≥2 nights

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Consecutive patients fulfilling the institutional criteria for inclusion into the routine PMI-screening
  • aged 40-85 years
  • at increased cardiovascular risk
  • undergoing inpatient, noncardiac, elective or emergent surgery
  • postoperative stay of ≥2 nights at the participating institution
  • orthopaedic, traumatology, vascular, spinal, thoracic, neurosurgical, and visceral surgery.

Exclusion criteria

Exclusion Criteria:

  • patients with cardiac surgery or interventions in the last 14 days
  • chronic renal failure under dialysis, renal transplant surgery
  • moderate-to-severe dementia
  • previous inclusion within 5 days
  • documented refusal to use of their data for research purposes or refusal of further use during follow-up
  • Patients declining consent for follow-up will be excluded from follow-up analyses.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
900 participants (estimated)
Patient registry
No

Groups and cohorts

  • Before implementation

    Patients included before implementation of the PMI-screening

    Other: Patient assessment and follow-up

  • After implementation

    Patients included after implementation of the PMI-screening

    Other: Patient assessment and follow-up

Interventions

  • OtherPatient assessment and follow-up

    There is no study-specific intervention. The investigators will record data generated by clinical activity before, during and after implementation of the PMI-screening. Follow-up data and the final PMI event adjudication will be the only data generated specifically for this study.

06

What researchers measure

Primary outcomes

  1. Perioperative Myocardial Infarction/Injury (PMI)-Screening (Reach)

    Percentage of patients eligible for PMI-screening according to inclusion criteria, but not screened during the implementation phase (defined as no or only one measurement of hs-cTn done during screening days)

    Time frame: during the hospital stay (up to postoperative day 2)

  2. Incidence of PMI

    Percentage of patients experiencing PMI following noncardiac surgery

    Time frame: after the surgery until postoperative day 2

  3. Cardiology consultation (Fidelity)

    Percentage of patients with detected PMI by PMI-screening on screening days, seen vs. not seen by a cardiologist

    Time frame: during hospital stay (up to postoperative day 5)

  4. Diagnostic challenge

    Number of cases with mismatch of initial classification of PMI aetiology (and management pathway) at time of consultation versus final adjudication. In case of two differential diagnoses stated on the cardiology consultation, mismatch is seen when none of the diagnoses correspond to the final adjudication. If three or more differential diagnoses are stated, mismatch is seen in any case even if the final adjudication diagnosis is stated

    Time frame: during hospital stay (up to postoperative day 5)

  5. Barriers to implementation

    Barriers to implementation will be assessed by a semi-quantitive questionnaire complemented by qualitative focus group including the local investigators and representatives of cardiology and anaesthesiology

    Time frame: following the post-implementation period (6 months after implementation)

Secondary outcomes

  1. Medicoeconomic impact

    Cost of postoperative blood draws on day 1 and 2, length of hospital stay, days on intensive care unit, consultations within day 1-3, ECG within day 1-3, cardiac stress testing within 30 days, and cardiac catheterisation within 30 days, denoted in Swiss Francs

    Time frame: Within 3 - 30 days following surgery

  2. Resource Usage

    Number of postoperative blood draws on day 1 and 2, length of hospital stay, days on intensive care unit, consultations within day 1-3, ECG within day 1-3, cardiac stress testing within 30 days, and cardiac catheterisation within 30 days

    Time frame: Within 3 - 30 days following surgery

  3. Major adverse cardiac events (MACE)

    Occurrence and timing of a composite of major adverse cardiac events (MACE) within twelve months, consisting of: All-cause death, acute myocardial infarction Type 1, survived sudden cardiac death, and Acute heart failure

    Time frame: 1 year

  4. Complications of cardiology diagnostics

    Number of inappropriate interventions or complications of cardiology diagnostics and interventions, consisting of: Overtreatment (Coronary angiographies showing normal coronaries), complications of cardiac interventions (myocardial infarction, stroke, death)

    Time frame: 30 days

  5. Major bleeding

    Bleeding Academic Research Consortium Typ 3-5

    Time frame: Postoperative day 1 - 1 year (blinding of first 24h following surgery)

07

Study locations

5 sites
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Data sharing with other research groups will be the responsibility of the PI.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2021 (actual). Primary completion is estimated for Dec 2026, 65 months after the start.

Of 298 non-industry observational studies under Myocardial Infarction, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 140. This study's planned 65 months is above that.

Counting every sponsor, half of 335 studies reached it within 48 months; a quarter within 18 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2023
First posted
May 16, 2023
StartActual
Jul 1, 2021
Primary completionEst.
Dec 2026
CompletionEst.
Jul 2027
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05859620
Collaborators
Luzerner Kantonsspital, Kantonsspital Olten, Medical University Innsbruck, University Hospital, Geneva, Bürgerspital Solothurn
Responsible party
Sponsor
First posted
May 16, 2023
Start date
Jul 1, 2021
Primary completion
Dec 2026 (estimated)
Completion
Jul 2027 (estimated)
Last update
May 5, 2026

Study contacts

Christian Puelacher, MD-PhD
principal investigator · University Hospital, Basel, Switzerland
Christian Müller, Prof.
study director · University Hospital, Basel, Switzerland

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion